Email from IMU...Dear all,Hello from Leslie ChongLast week we...

Email from IMU...

Dear all,

Hello from Leslie Chong

Last week we announced concurrently here in Australia, and the US by City Of Hope, a world-renowned independent cancer research and treatment center near Los Angeles, a licensing agreement for the patents covering a novel combination immunotherapy called onCARlytics, which unleashes a CD19 expressing oncolytic virus to enable CD19 directed chimeric antigen receptor (CAR) T cell therapies to target solid tumours, which are currently otherwise difficult to treat with CD19 directed CAR T cell therapy alone.

Please click here to view the release.

Today we released an extensive newsletter detailing onCARlytics which provides a wealth of information.

Please click here to read the newsletter and discover how onCARlytics is going to truly make a positive difference in our ongoing efforts to defeat the scourge of cancer in all its forms.

The worldwide exclusive licence of the patents covering the cell therapy technology, which includes CF33-CD19, known as onCARlytics or an agent that tags cancer cells for CAR T cell destruction, was developed at City of Hope.

City of Hope scientists led by Saul Priceman, Ph.D., have combined two potent immunotherapies. Imugene’s CD19 oncolytic virus and CD19 CAR T cell therapy — with the goal of targeting and eradicating solid tumours that are otherwise difficult to treat with CAR T cell therapy alone.

Our new collaborator Dr Saul Priceman said, “Our research demonstrates that oncolytic viruses are a powerful and promising approach that can be combined strategically with CAR T cell therapy to effectively target solid tumours in patients. This therapeutic platform addresses two major challenges that make solid tumours so difficult to treat with immunotherapy. There are limited solid tumour targets that T cells can be redirected against with CARs. Solid tumours are surrounded by a brick wall -- a so-called immunosuppressive tumour microenvironment. When a CAR T cell attempts to enter the tumour, survive, and kill cancer cells, it can’t effectively because of this barrier.”

I've never been more excited about the transformational opportunities we are developing. I encourage you to continue to follow our progress.

As always, many thanks for your enduring support.

Warmest,
Leslie